How to buy Catalent stock | $131.78

Catalent Inc is a drug manufacturers-specialty & generic business based in the US. Catalent shares (CTLT) are listed on the NYSE and all prices are listed in US Dollars. Catalent employs 17,300 staff and has a trailing 12-month revenue of around 0.00.

Catalent stock price (NYSE: CTLT)

Use our graph to track the performance of CTLT stocks over time.

Catalent shares at a glance

• Key figures

Information last updated 2021-10-15.

Latest market close	$131.78
52-week range	$86.43 - $142.64
50-day moving average	$134.54
200-day moving average	$116.79
Wall St. target price	$150.92
PE ratio	41.4051
Dividend yield	N/A (0%)
Earnings per share (TTM)	$3.11

Buy Catalent shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Catalent stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Catalent price performance over time

Historical closes compared with the close of $131.78 from 2021-10-20

1 week (2021-10-14)	2.20%
1 month (2021-09-21)	-3.17%
3 months (2021-07-21)	16.06%
6 months (2021-04-21)	18.43%

1 year (2020-10-21)	42.60%
2 years (2019-10-21)	170.98%
3 years (2018-10-19)	218.54%
5 years (2016-10-21)	440.75%

Is Catalent under- or over-valued?

Valuing Catalent stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalent's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalent's P/E ratio

Catalent's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 41x. In other words, Catalent shares trade at around 41x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Catalent's PEG ratio

Catalent's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.1046. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalent's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Catalent's EBITDA

Catalent's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $954 million.

The EBITDA is a measure of a Catalent's overall financial performance and is widely used to measure a its profitability.

Catalent financials

Revenue TTM	$4 billion
Operating margin TTM	16.63%
Gross profit TTM	$1.4 billion
Return on assets TTM	4.92%
Return on equity TTM	15.04%
Profit margin	14.63%
Book value	$22.96
Market capitalisation	$22 billion

TTM: trailing 12 months

Shorting Catalent shares

There are currently 2.1 million Catalent shares held short by investors – that's known as Catalent's "short interest". This figure is 2.6% down from 2.2 million last month.

There are a few different ways that this level of interest in shorting Catalent shares can be evaluated.

Catalent's "short interest ratio" (SIR)

Catalent's "short interest ratio" (SIR) is the quantity of Catalent shares currently shorted divided by the average quantity of Catalent shares traded daily (recently around 1.1 million). Catalent's SIR currently stands at 1.86. In other words for every 100,000 Catalent shares traded daily on the market, roughly 1860 shares are currently held short.

However Catalent's short interest can also be evaluated against the total number of Catalent shares, or, against the total number of tradable Catalent shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catalent's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Catalent shares in existence, roughly 10 shares are currently held short) or 0.0125% of the tradable shares (for every 100,000 tradable Catalent shares, roughly 13 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Catalent.

Find out more about how you can short Catalent stock.

Catalent share dividends

We're not expecting Catalent to pay a dividend over the next 12 months.

Catalent share price volatility

Over the last 12 months, Catalent's shares have ranged in value from as little as $86.43 up to $142.64. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Catalent's is 1.3889. This would suggest that Catalent's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Catalent overview

Catalent, Inc. , together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services.

Frequently asked questions

What percentage of Catalent is owned by insiders or institutions?
Currently 0.309% of Catalent shares are held by insiders and 102.736% by institutions. How many people work for Catalent?
Latest data suggests 17,300 work at Catalent. When does the fiscal year end for Catalent?
Catalent's fiscal year ends in June. Where is Catalent based?
Catalent's address is: 14 Schoolhouse Road, Somerset, NJ, United States, 08873 What is Catalent's ISIN number?
Catalent's international securities identification number is: US1488061029 What is Catalent's CUSIP number?
Catalent's Committee on Uniform Securities Identification Procedures number is: 148806102